RE:13- 3-4 Star Funds are Buying Vs. 5- 3-4 Star Funds Selling Great Results. Shorts manipulating stock price for controlled exit. SP should rise significantly as shorts cover and maybe even go long as positive results continue to become more apparent. Congratulations to management for making successful changes and all shareholders holding longer term on this ride.
First Quarter 2017 Financial Results
Total revenue for the first quarter of 2017 increased to $68.3 million, a 33.2% increase over the same period the prior year. Total case volume increased by 457 cases, or 11.5%, to 4,431 cases in the first quarter of 2017, as compared to the same period last year. Revenue per case increased to $15,415 or 19.5% in the first quarter of 2017, as compared to $12,902 in the same period last year. This increase was due to the growth of our Hospital and Ancillary divisions. The increase in total revenue and total case volume in the first quarter of 2017 compared to the same quarter last year was primarily due to organic growth.
Net loss attributable to Nobilis for the first quarter of 2017 was $2.4 million, or $0.03 per fully diluted share, as compared to net loss attributable to Nobilis of $5.0 million, or $0.07 per fully diluted share, in the first quarter of 2016. Net loss in the first quarter of 2017 included a $0.4 million change in fair value of warrants and stock options.
Adjusted EBITDA1 for the first quarter of 2017, which adds back certain non-cash and non-recurring expenses, was $2.0 million, an increase of 473.5% over $0.4 million in the same quarter last year.
Total cash was $31.2 million, accounts receivable was $102.7 million and total debt was $74.8 million as of March 31, 2017, compared to $24.6 million, $125.0 million and $67.8 million, respectively, at December 31, 2016.
The Board of Directors recently approved a share repurchase program under which the Company may repurchase up to 5% of shares outstanding, or approximately 4 million shares, subject to any applicable rules and regulations and/or banking requirements.
Full Year 2017 Guidance
Nobilis reiterates the full year 2017 guidance originally provided on March 13, 2017.
- Revenue in the range of $310.0 million to $325.0 million.
- Adjusted EBITDA1 of $40.0 million to $45.0 million.
Read more at https://www.stockhouse.com/companies/bullboard?symbol=hlth&postid=26190758#fAqsKPsB6PhVk4GJ.99 BigGreenWhale01 wrote:
Names such as Blackrock, Mellon, ProShares, Schwab, Rydex, Fidelity, Royce, Sun America, Principal and Vanguard. These funds have very deeeeep pockets and when they really get onside and greater weight HLTH, the SP will move north and smoke the shorts. They're no idiots.
Any way you dissect the Qtr 1/17 results, it reveals a very positive direction for the company. I particularly liked the +400% increase in 1st Qtr revenues Y/Y. As an investor, I don't sweat the little stuff. Growth cost.. full stop. HLTH's growth over a company.. ohhh.. let's say CRH.. is far better and the market is finally recognizing the flaws in CRH's model whom I've written earlier is far more worthy of short interest than Nobilis.
As Nobilis1 wrote earlier.. Time to move on. There's nothing cor you here anymore.